$PFE Pfizer &amp; Biontech announce early positive data from an ongoing phase1/2 study of mrna-based vaccine candidate against sars-cov-2. The companies are expecting to manufacture up to 100 million doses by the end of 2020 &amp; potentially more than 1.2billion doses by the end of 2021